US20190060216A1 - Anti-pollution compositions containing bacillus coagulans - Google Patents

Anti-pollution compositions containing bacillus coagulans Download PDF

Info

Publication number
US20190060216A1
US20190060216A1 US16/117,146 US201816117146A US2019060216A1 US 20190060216 A1 US20190060216 A1 US 20190060216A1 US 201816117146 A US201816117146 A US 201816117146A US 2019060216 A1 US2019060216 A1 US 2019060216A1
Authority
US
United States
Prior art keywords
bacillus coagulans
composition
probiotic bacteria
skin
mtcc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/117,146
Other languages
English (en)
Inventor
Muhammed Majeed
Kalyanam Nagabhushanam
Lakshmi Mundkur
Shaheen Majeed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sami Chemicals and Extracts Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of US20190060216A1 publication Critical patent/US20190060216A1/en
Assigned to SAMI LABS LIMITED reassignment SAMI LABS LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MAJEED, MUHAMMED, DR, MAJEED, SHAHEEN, MR, MUNDKUR, LAKSHMI, DR, NAGABHUSHANAM, KALYANAM, DR
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/524—Preservatives

Definitions

  • the present invention relates to probiotic compositions. More specifically, the present invention pertains to compositions comprising probiotic microorganism Bacillus coagulans MTCC 5856 for use as an anti-pollutant and skin rejuvenation/cleansing agent.
  • Skin the largest organ in the mammalian body, plays the role of a barrier by conferring protection from mechanical impacts and pressure, variations in temperature, micro-organisms, radiation and chemicals.
  • the skin is exposed to a variety of pollutants thereby causing premature skin ageing, pigmentation spots, or acne or lead to more serious dermatological issues such as atopic dermatitis, psoriasis, and even skin cancer (English, J. S., R. S. Dawe, and J. Ferguson, Environmental effects and skin disease. Br Med Bull, 2003. 68: p. 129-42).
  • the main sources of pollution include particulate matter, polycyclic aromatic hydrocarbons (PAHs), volatile organic compounds (VOCs), nitrogen and sulfur oxides, carbon monoxide, ozone, and heavy metals (Baudouin, C., et al., Environmental pollutants and skin cancer. Cell Biol Toxicol, 2002. 18(5): p. 341-8).
  • the toxic gases (CO2, CO, SO2, NO, NO2), low molecular weight hydrocarbons, persistent organic pollutants (e.g., dioxins), heavy metals (e.g., lead, mercury) and particulate matter (PM) form the primary pollutants which are formed from the source.
  • Secondary pollutants which include ozone (O3), NO2, peroxy acetyl nitrate, hydrogen peroxide and aldehydes are formed in the atmosphere through chemical and photochemical reactions involving primary pollutants (Kampa, M. and E. Castanas, Human health effects of air pollution. Environ Pollut, 2008. 151(2): p. 362-7).
  • the inflammatory cascade is activated by these alterations, which results in increased production of pro inflammatory cytokines such as interleukin (IL)-1 or IL 8, resulting in skin lesions and deterioration of skin appearance (Mancebo, S. E. and S. Q. Wang, Recognizing the impact of ambient air pollution on skin health. J Eur Acad Dermatol Venereol, 2015. 29(12): p. 2326-32).
  • IL interleukin
  • MMPs matrix metalloproteinase
  • enzymes that degrade the matrix protein's elastin and collagen which, if not prevented, can result in marked reduction in skin elasticity and increased wrinkling
  • Misom, L., P. Moller, and S. Loft Oxidative stress-induced DNA damage by particulate air pollution. Mutat Res, 2005. 592(1-2): p. 119-37; Moller, P. and S. Loft, Oxidative damage to DNA and lipids as biomarkers of exposure to air pollution. Environ Health Perspect, 2010. 118(8): p. 1126-36).
  • UVA can penetrate deeper into the skin in comparison to UVB and contributes to photoaging, photocarcinogenesis and photodermatosis and increase oxidative stress in fibroblasts and cells which are deeper inside the skin.
  • Blue light (light from mobile, TV, laptop/desktop screens) is reported to exert similar effect (Godley et al., Blue Light Induces Mitochondrial DNA Damage and Free Radical Production in Epithelial Cells, The Journal Of Biological Chemistry, 2005, 280(22):21061-21066).
  • Oxidative stress is defined as the imbalance in the redox characteristics of cellular environments resulting from (1) aberrant biochemical processes leading to the production of reactive species, (2) exposure to damaging agents (i.e., environmental pollutants and radiations), or (3) limited capabilities of endogenous antioxidant systems.
  • Reactive oxygen and nitrogen species (ROS/RNS) produced under oxidative stress are known to damage all cellular biomolecules (lipids, sugars, proteins, and polynucleotides).
  • Cellular defence systems to prevent uncontrolled ROS increase include nonenzymatic molecules (glutathione, vitaminutes A, C, and E, and several antioxidants present in foods) and enzymatic scavengers of ROS, with superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPX) being the best-known mechanisms.
  • nonenzymatic molecules glutathione, vitaminutes A, C, and E, and several antioxidants present in foods
  • SOD superoxide dismutase
  • CAT catalase
  • GPX glutathione peroxidase
  • probiotic microorganisms for therapeutic purposes due to the common understanding that probiotic biological activities are strain specific.
  • the genus-species-strain specific differences in biological activities are to be evaluated to link probiotics to specific health effects and also to enable accurate surveillance and epidemiological studies as indicated in Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food London, Ontario, Canada, April 30 and May 1, 2002—See Section 3.1.
  • a superior probiotic which can exert an excellent anti-pollution effect and rejuvenate the skin is still warranted.
  • the present invention overcomes the aforesaid technical problem by disclosing probiotic microorganism Bacillus coagulans MTCC 5856 as an effective anti-pollution agent and an excellent antioxidant.
  • the present invention fulfils the aforesaid objective and provides further related advantages.
  • the present invention discloses the anti-pollution effects of probiotic bacteria Bacillus coagulans MTCC 5856 on the skin of mammals. More specifically the invention discloses the use of probiotic bacteria Bacillus coagulans MTCC 5856 in protecting the skin against the harmful effects of UV and different environmental pollutants. The use of Bacillus coagulans MTCC 5856, as an antioxidant, skin rejuvenating and cleansing agent is also disclosed.
  • FIG. 1 a is the graphical representation showing the decrease in ROS production by probiotic bacteria Bacillus coagulans MTCC 5856 in mouse fibroblast cells, exposed to UV-A.
  • FIG. 1 b is the graphical representation showing the percentage ROS scavenging by probiotic bacteria Bacillus coagulans MTCC 5856 in mouse fibroblast cells, exposed to UV-A.
  • FIG. 2 a is the graphical representation showing the decrease in ROS production by probiotic bacteria Bacillus coagulans MTCC 5856 in human keratinocytes, exposed to UV-B.
  • FIG. 2 b is the graphical representation showing the percentage ROS scavenging by probiotic bacteria Bacillus coagulans MTCC 5856 in human keratinocytes, exposed to UV-B.
  • FIG. 3 a is the graphical representation showing the decrease in ROS production by probiotic bacteria Bacillus coagulans MTCC 5856 in mouse fibroblast cells, exposed to sodium lauryl sulfate.
  • FIG. 3 b is the graphical representation showing the percentage ROS scavenging by probiotic bacteria Bacillus coagulans coagulans MTCC 5856 in mouse fibroblast cells, exposed to sodium lauryl sulfate.
  • FIG. 4 a is the graphical representation showing the decrease in ROS production by probiotic bacteria Bacillus coagulans MTCC 5856 in human keratinocytes, exposed to mixture of heavy metals
  • FIG. 4 b is the graphical representation showing the percentage ROS scavenging by probiotic bacteria Bacillus coagulans coagulans MTCC 5856 in human keratinocytes, exposed to mixture of heavy metals
  • FIG. 5 a is the graphical representation showing the increase in cell survival by probiotic bacteria Bacillus coagulans MTCC 5856 in human keratinocytes, exposed to mixture of benzpyrene (PAH) and UV irradiation
  • FIG. 5 b is the graphical representation showing the percentage protection against cell death in human keratinocytes, exposed to mixture of benzpyrene (PAH) and UV irradiation by probiotic bacteria Bacillus coagulans coagulans MTCC 5856
  • FIG. 6 a is the graphical representation showing the increase in cellular glutathione levels by probiotic bacteria Bacillus coagulans MTCC 5856 in human keratinocytes, exposed to UV-A.
  • FIG. 6 b is the graphical representation showing the increase in cellular glutathione levels by probiotic bacteria Bacillus coagulans MTCC 5856 in human keratinocytes, exposed to UV-B.
  • FIG. 7 a is the graphical representation showing the increase in cellular superoxide dismutase activity by probiotic bacteria Bacillus coagulans MTCC 5856 in human keratinocytes, exposed to UV-A.
  • FIG. 7 b is the graphical representation showing the increase in cellular superoxide dismutase activity by probiotic bacteria Bacillus coagulans MTCC 5856 in human keratinocytes, exposed to UV-B.
  • the present invention discloses a composition containing probiotic bacteria Bacillus coagulans for protecting mammalian skin against the harmful effects of UV radiation and environmental pollutants.
  • the probiotic bacteria Bacillus coagulans is present in the form of a spore or viable bacilli.
  • the environmental pollutants are selected from the list consisting of, but not limited to, particulate matter, polycyclic aromatic hydrocarbons (PAHs), volatile organic compounds (VOCs), detergents, nitrogen and sulfur oxides, carbon monoxide, ozone, and heavy metals.
  • the probiotic bacteria confers skin protection by increasing the levels of anti-oxidants and decreasing ROS levels.
  • the Bacillus coagulans strain is preferably Bacillus coagulans MTCC 5856.
  • the composition is formulated with pharmaceutically/cosmeceutically acceptable excipients, adjuvants, bases, diluents, carriers, conditioning agents, bioavailability enhancers, and preservatives and/or incorporated into formulations containing skin care ingredients and administered topically in the form of creams, gels, lotions, powder, serum, oil, suspensions, ointments, soaps, scrubs, emulsions, and compacts.
  • the invention discloses a method for cleansing a rejuvenating mammalian skin exposed to environmental pollutants and UV radiation, said method comprising step of administering an effective dose of a composition containing probiotic bacterial Bacillus coagulans to mammals in need of such effect.
  • the probiotic bacteria Bacillus coagulans is present in the form of a spore or viable bacilli.
  • the environmental pollutants are selected from the list consisting of, but not limited to, particulate matter, polycyclic aromatic hydrocarbons (PAHs), volatile organic compounds (VOCs), detergents, nitrogen and sulfur oxides, carbon monoxide, ozone, and heavy metals.
  • the probiotic bacteria rejuvenates the skin by increasing the levels of anti-oxidants and decreasing ROS levels.
  • the Bacillus coagulans strain is preferably Bacillus coagulans MTCC 5856.
  • the composition is formulated with pharmaceutically/cosmeceutically acceptable excipients, adjuvants, bases, diluents, carriers, conditioning agents, bioavailability enhancers, and preservatives and/or incorporated into formulations containing skin care ingredients and administered topically in the form of creams, gels, lotions, powder, serum, oil, suspensions, ointments, soaps, scrubs, emulsions, and compacts.
  • the invention discloses a composition containing probiotic bacteria Bacillus coagulans for use as an antioxidant.
  • the composition containing probiotic bacteria Bacillus coagulans is used in the therapeutic management of mammalian cellular oxidative stress.
  • the probiotic bacteria Bacillus coagulans is present in the form of a spore or viable bacilli.
  • the Bacillus coagulans strain is preferably Bacillus coagulans MTCC 5856.
  • composition is formulated with pharmaceutically/cosmeceutically acceptable excipients, adjuvants, bases, diluents, carriers, conditioning agents, bioavailability enhancers, and preservatives and/or incorporated into formulations containing skin care ingredients and administered orally or topically in the form of tablet, capsule, powder, emulsions, solution, creams, gels, lotions, powder, serum, oil, suspensions, ointments, soaps, scrubs, emulsions, and compacts, suited for nutraceutical, cosmeceutical and nutri-cosmetic applications.
  • In vitro anti-pollution tests are based on cell models that are set up to reflect the in vivo state under laboratory conditions. They are usually carried out using keratinocyte or fibroblast cell lines. The impact of pollution on skin cells and the effect of the anti-pollution treatment are assessed by the quantification of specific markers and cell parameters.
  • ROS assay A cell permeable, non-fluorescent dye, 2′,7′-dichlorofluorescein diacetate (DCFH-DA) enters the cell and the acetate group on DCFH-DA is cleaved by cellular esterases, trapping the non-fluorescent DCFH inside the cell. Subsequent oxidation by reactive oxygen species generated by ferrous sulphate in the cells, yields the fluorescent DCF which can be detected at 485/520 Ex:Em wavelength. The scavenging activity of sample is indicated by the decrease in fluorescence when compared to the control without antioxidant.
  • DCFH-DA 2′,7′-dichlorofluorescein diacetate
  • Human HaCaT keratinocyte cells/mouse fibroblast cells were maintained in DMEM containing 25 mM glucose with 10% heat-inactivated fetal calf serum with antibiotics at 37° C. and 5% CO 2 . When the cells were 70-80% confluent, they were trypsinized, washed and seeded in 96 well plates at a density seeded at a density of 1 ⁇ 10 4 cells/well. Cells were allowed to adhere and form a monolayer for 24 hours. Cells were pretreated with varying non toxic concentrations of Bacillus coagulans MTCC 5856 in PBS for 60 minutes before exposing to the pollutant. Cells were exposed to the following pollutants
  • PAHs Polycyclic aromatic hydrocarbons
  • PACs Polycyclic aromatic hydrocarbons
  • PAHs themselves are biologically inert and require metabolic activation in order to exert genotoxicity PAHs absorb light in the UVA region. react with oxygen or other molecules to generate reactive intermediates (Yu H, Xia Q, Yan J, et al. Photoirradiation of polycyclic aromatic hydrocarbons with UVA light—a pathway leading to the generation of reactive oxygen species, lipid peroxidation, and dna damage. Int J Environ Res Public Health. 2006; 3: 348-354) Thus, PAHs can be “activated” by light irradiation to cause photo-induced cytotoxicity. Thus photoirradiation of PAHs with UVA irradiation represents a pollutant which causes cytotoxicity and DNA damage.
  • Human HaCaT keratinocyte cells/mouse fibroblast cells were seeded at a density of 1 ⁇ 10 4 cells/well in 96 well plates. Cells were allowed to adhere and form a monolayer for 24 hours. They were pretreated with different cell densities of Bacillus coagulans MTCC 5856 for 60 minutes, exposed to UVA at an intensity of 15 Joules/m 2 in the presence of Benzpyrene a PAH at 0.5 mM for 30 minutes washed with sterile buffer and fresh culture medium (5% of FBS) with respective concentrations of probiotic bacteria Bacillus coagulans MTCC 5856 were added followed by incubation for 6 hours at 37° C. in a CO 2 incubator.
  • Neutral Red 50 pg/mL (3-amino-7-dimethylamino-2-methylphenazine hydrochloride), was added to the cells for 3 hours.
  • the uptake of NR by the cells was determined by lysing the cells and reading the absorbance at 540 nm in a spectrophotometer (Guidelines, O., Genetic Toxicology: Bacterial Reverse Mutation Assay # 471. 1997)
  • Bacillus coagulans MTCC 5856 exerted antipollution effects by protecting the keratinocytes from cellular cytotoxicity induced by photoirradiation of PAHs with UVA irradiation in a dose dependant manner ( FIG. 5 a ).
  • Maximum ROS scavenging (30.6%) was observed at cells numbers of 10 3 cells/well ( FIG. 5 b )
  • Cellular anti oxidants are depleted by pollutants.
  • Bacillus coagulants MTCC 5856 to increase these anti oxidant enzymes in the cells was studied in vitro.
  • Cellular gultathione (GSH) and superoxide dismutase (SOD) levels were estimated in human keratinocytes (Peskin A V, Winterbourn C C. Assay of superoxide dismutase activity in a plate assay using WST-1. Free Radic Biol Med. 2017; 103:188-191.)
  • SOD assay The activity of SOD was measured by WST-1 method using a kit as per the manufacturer's instructions (Elabsciences).
  • Xanthine Oxidase (XO) can catalyze WST-1 react with O 2 . ⁇ to generate a water-soluble formazan dye.
  • SOD can catalyze the disproportionation of superoxide anions, so the reaction can be inhibited by SOD, and the activity of SOD is negatively correlated with the amount of formazan dye. Therefore, the activity of SOD can be determined by the colorimetric analysis of WST-1 products.
  • Glutathione (GSH) content Reduced glutathione was determined based on the method of Moron, Depierre. GSH is measured by its reaction with DTNB to give a yellow colored complex with maximum absorption at 412 nm. 100 ⁇ l of the test sample (CELL LYSATE) was mixed with 10 ⁇ l of 50% TCA was added and centrifuged at 2000 rpm for 10 minute. 30 ⁇ l of the supernatant was mixed with 50 ⁇ l of 0.2 M sodium phosphate buffer (pH 8.0) and 200 ⁇ l of freshly prepared 0.6 mM DTNB and the intensity of yellow colour formation was measured at 412 nm. A standard graph was prepared with different concentrations (1000-62.5 ⁇ M) of GSH. The GSH content of the sample was calculated from the standard graph and expressed as ⁇ mol/mg protein.
  • Bacillus coagulans MTCC 5856 increased the glutathione content in a dose dependant manner ( FIGS. 6 a and 6 b ).
  • the activity of SOD was also increased in a dose depended manner in cells treated with Bacillus coagulans MTCC 5856 ( FIGS. 7 a and 7 b ) indicating that Bacillus coagulans MTCC 5856 is not only an effective antioxidant, but also rejuvenates skin by increasing the antioxidant content in the cells.
  • Bacillus coagulans MTCC 5856 was observed to exert anti-pollution effects by conferring protection against UV and other pollutants by scavenging the ROS produced as a result of exposure to these pollutants. Bacillus coagulans MTCC 5856 also acts as an effective anti-oxidant and also increases the antioxidant content in the cells. The present invention reports that Bacillus coagulans MTCC 5856 can be used not only as an anti-oxidant for the management of different pathological conditions but also as an effective skin rejuvenating and cleansing agent by conferring protection against pollutants and increasing the anti-oxidant content, which can have potential applications in skin care/cosmetic industry.
  • composition containing Bacillus coagulans MTCC 5856 may be formulated with pharmaceutically/cosmeceutically acceptable excipients, adjuvants, bases, diluents, carriers, conditioning agents, bioavailability enhancers, antioxidants and preservatives and/or incorporated into formulations containing anti-aging ingredients and administered topically in the form of creams, gels, lotions, powder, serum, oil, suspensions, ointments, soaps, scrubs, emulsions, and compacts.
  • one or more skin care ingredients are selected from the group consisting of, but not limited to, Alpha Lipoic Acid, oxyresveratrol, Beet root extract, Boswellia serrata Extract, ⁇ boswellic acids, Boswellia serrata oil, Centella asiatica Extract, triterpenes, Garcinia indica extract, anthocyanins, Cocos nucifera extract and juice, Coleus forskohlii Extract, forskolin, Coleus forskohlii Oil, Tetrahydropiperine, Ellagic Acid, Gallnut Extract, polyphenols, Galanga Extract, Glycyrrhizinic Acid, Green Tea Extract, Epigallocatechin Gallate, Licorice extract, MonoAmmonium Glycyrrhizinate, Limonoids, Oleanolic Acid, Cosmetic peptides (Oleanolic acid linked to Lys-Thr-Thr-Lys-Ser, Oleanolic acid linked to Lys-Val-Lys), Ol
  • one or more anti-oxidants and anti-inflammatory agents are selected from the group consisting of, but not limited to, vitamin A, D, E, K, C, B complex, rosmarinic acid, Alpha Lipoic Acid, oxyresveratrol, Ellagic Acid, Glycyrrhizinic Acid, Epigallocatechin Gallate, plant polyphenols, Glabridin, moringa oil, oleanolic acid, Oleuropein, Carnosic acid, urocanic acid, phytoene, lipoid acid, lipoamide, ferritin, desferal, billirubin, billiverdin, melanins, ubiquinone, ubiquinol, ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate, tocopherols and derivatives such as vitamin E acetate, uric acid, ⁇ -glucosylrutin, calalase and the superoxide dismutase, glutathione, selenium compounds,
  • one or more bioavailability enhancers are selected from the group, but not limited to, piperine, tetrahydropiperine, quercetin, Garlic extract, ginger extract, and naringin.
  • Tables 1-4 provide illustrative examples of skin care formulations containing Bacillus coagulans MTCC 5856 (commercially available as LACTOSPORE)
  • Bacillus coagulans MTCC 5856 100 cfu to 2 billion cfu Tetrahydrocurcumin, licorice extract, Pterostilbene, Tetrahydropiperine, Galanga extract, Niacinamide Other ingredients/Excipients Aqua, Avobenzone, Octyl methoxy cinnamate, Octocrylene, Benzophenone-3, Octyl Salicylate, Glyceryl Stearate SE, Sorbitan Stearate & Sucrose Cocoate, Polysorbate 20, Glycerin, Cetostearyl Alcohol, Cetearyl Olivate (and) Sorbitan Olivate, Stearic acid, Isopropyl myristate, Garcinia indica Seed Butter, Caprylic/Capric Triglyceride, Propylene Glycol, Butyloctyl Salicylate, Cyclopentasiloxane, Dimethiconol, Dimethicone Crosspolymer (and
  • Bacillus coagulans MTCC 5856 100 cfu to 2 billion cfu Cocus nucifera extract, walnut scrub, neem oil, Niacinamide, lemon peel extract, Vitamin E acetate
  • Other ingredients/Excipients Aqua Glycerin, Caprylic/Capric Triglyceride, Lauryl Glucoside, Sorbitan Stearate & Sucrose Cococate, Isopropyl Myristate, Isopropyl Palmitate & Pentaerthrityl Tetraisostearate, Cetyl Palmitate, Stearic acid, Cetostearyl Alcohol, CI 77891, Juglans Regia (Walnut) Shell Powder, Zea Mays (corn) Starch, Azadirachta Indica (Neem) Seed Oil, Phenoxyethanol & Methylisothiazolinone, Fragrance, Acrylates/C10-30 Alkyl Acrylate Crosspolymer,
  • Tables 5 and 6 provide illustrative examples of formulations containing Bacillus coagulans for use an antioxidant and maintaining the redox equilibrium of the cells.
  • Bacillus coagulans Tablet Active Ingredients Bacillus coagulans MTCC 5856: 2 billion cfu Excipients Microcrystalline cellulose, Colloidal silicon dioxide, Magnesium stearate
  • Bacillus coagulans MTCC 5856 2 billion cfu Excipients Microcrystalline cellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
US16/117,146 2017-08-31 2018-08-30 Anti-pollution compositions containing bacillus coagulans Abandoned US20190060216A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741030867 2017-08-31
IN201741030867 2017-08-31

Publications (1)

Publication Number Publication Date
US20190060216A1 true US20190060216A1 (en) 2019-02-28

Family

ID=65436441

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/117,146 Abandoned US20190060216A1 (en) 2017-08-31 2018-08-30 Anti-pollution compositions containing bacillus coagulans

Country Status (10)

Country Link
US (1) US20190060216A1 (ja)
EP (1) EP3675812A4 (ja)
JP (1) JP7262445B2 (ja)
KR (1) KR102376076B1 (ja)
CN (1) CN111050748A (ja)
AU (1) AU2018324045A1 (ja)
BR (1) BR112020004050A2 (ja)
CA (1) CA3074267C (ja)
RU (1) RU2745755C1 (ja)
WO (1) WO2019046508A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190083378A1 (en) * 2017-09-21 2019-03-21 Muhammed Majeed Process for preparing tripeptide containing oleanolic acid and its therapeutic applications thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102539445B1 (ko) * 2020-11-25 2023-06-05 (주)케어젠 미세먼지에 의한 세포 손상 방지 활성을 갖는 펩타이드 및 이의 용도
CN113234791B (zh) * 2021-06-25 2022-09-23 长沙和光生物科技有限公司 一种凝结芽孢杆菌的计数检测方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2287451C (en) 1997-04-18 2014-06-10 Sean Farmer Topical use of probiotic bacillus spores to prevent or control microbial infections
JP4204096B2 (ja) * 1998-05-15 2009-01-07 花王株式会社 皮膚疾患改善剤
FR2889057B1 (fr) 2005-08-01 2008-07-18 Oreal Composition cosmetique et/ou dermatologique pour la prevention et/ou le traitement des peaux sensibles ou seches
GB0524873D0 (en) 2005-12-06 2006-01-11 New Royal Holloway & Bedford Bacterial production of carotenoids
FR2953408B1 (fr) 2009-12-08 2013-02-08 Oreal Microorganismes probiotiques a titre d'actif pour l'eclat du teint de la peau
EP2814457A2 (en) * 2012-02-14 2014-12-24 The Procter and Gamble Company Topical use of a skin-commensal prebiotic agent and compositions containing the same
US20150044317A1 (en) * 2012-02-28 2015-02-12 Ganeden Biotech, Inc. Topical Compositions for Reducing Visible Signs of Aging and Methods of Use Thereof
US9596861B2 (en) * 2013-12-24 2017-03-21 Sami Labs Limited Method of producing partially purified extracellular metabolite products from Bacillus coagulans and biological applications thereof
JP2017190298A (ja) 2016-04-13 2017-10-19 博 小田 体内で水素を産生する組成物、及びサプリメント

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190083378A1 (en) * 2017-09-21 2019-03-21 Muhammed Majeed Process for preparing tripeptide containing oleanolic acid and its therapeutic applications thereof
US10588844B2 (en) * 2017-09-21 2020-03-17 Sami Labs Limited Process for preparing tripeptide containing oleanolic acid and its therapeutic applications thereof

Also Published As

Publication number Publication date
AU2018324045A1 (en) 2020-03-19
WO2019046508A1 (en) 2019-03-07
EP3675812A1 (en) 2020-07-08
KR20200044870A (ko) 2020-04-29
BR112020004050A2 (pt) 2020-09-01
JP2020532530A (ja) 2020-11-12
CA3074267A1 (en) 2019-03-07
RU2745755C1 (ru) 2021-03-31
JP7262445B2 (ja) 2023-04-21
CA3074267C (en) 2022-10-25
CN111050748A (zh) 2020-04-21
KR102376076B1 (ko) 2022-03-18
EP3675812A4 (en) 2021-06-02

Similar Documents

Publication Publication Date Title
Lohézic-Le Dévéhat et al. Lichenic extracts and metabolites as UV filters
Paudel et al. Ramalin, a novel nontoxic antioxidant compound from the Antarctic lichen Ramalina terebrata
CA3074267C (en) Anti-pollution compositions containing bacillus coagulans
US11865203B2 (en) Skin care applications of extracellular metabolites from Bacillus coagulans
US10588844B2 (en) Process for preparing tripeptide containing oleanolic acid and its therapeutic applications thereof
EP3585356A1 (en) Sunscreen
Kapadia et al. Evaluation of skin cancer chemoprevention potential of sunscreen agents using the Epstein–Barr virus early antigen activation in vitro assay
CN114630650B (zh) 植物活性物及其防污染效果
Alnuqaydan Determination of Cancer Induction and Cell-Killing Potential of Beauty Products and Personal Care Products Using Human Skin Cells

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: SAMI LABS LIMITED, INDIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAJEED, MUHAMMED, DR;NAGABHUSHANAM, KALYANAM, DR;MUNDKUR, LAKSHMI, DR;AND OTHERS;REEL/FRAME:051833/0851

Effective date: 20200206

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION